Our Partners
Atomo's numerous partners utilise our unique, innovative technology to bring a range of high-quality rapid diagnostic tests to global markets.
We work with a number of highly reputable partners in the diagnostic testing space. As a result of these partnerships, Atomo's technology is available in over 30 countries worldwide.
NG Biotech
NG Biotech is a French innovative biotech company focusing on the development and manufacture of novel in vitro diagnostic tools for therapy monitoring at the point of care (Onsite).
Utilising Atomo's Pascal platform, NG's Precision+ pregnancy test offers results in 5 minutes through professional use channels. The blood-based test detects earlier and at a higher rate of accuracy than urine tests.
The NG Precision+ is available for purchase throughout Europe.
Viatris
Headquartered in the United States, with three global centres in Pittsburgh, Pennsylvania, U.S., Shanghai, China, and Hyderabad, India, Viatris operates approximately 40 manufacturing facilities that produce complex dosage forms, injectables, oral solid doses and active pharmaceutical ingredients.
Utilising Atomo's Galileo platform, Viatris' Mylan HIV Self Test is sold through lower-middle income markets across the world, creating additional avenues for HIV testing in markets where significantly more barriers to clinical testing exist.
Lumos Diagnostics
Lumos Diagnostics specialises in rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercialises proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases.
Utilising Atomo's Pascal platform, Lumos' FebriDx platform is sold in Europe and under review with the US FDA. The test is authorised to identify and differentiate viral from bacterial acute respiratory infection. With 99% accuracy, this test has reduced antibiotic prescriptions by 80%, leading to better efficiencies and lower costs.
Develop Future Tests With Us
Atomo’s unique technology presents an opportunity to improve existing products on the market with superior usability. Our integrated platforms can help users easily perform the tests on their own and improve performance, speed and reliability in a professional clinical setting.
We welcome dialogue with forward-thinking diagnostic partners who would like to explore co-developing tests for infectious diseases, allergy sensitivities, women’s health, men’s health, sexual health, heart health and other applications.
